Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation

Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation

Hematopoietic stem cell (HSC) transplantation is a desirable treatment for many non-malignant and malignant diseases, but its use requires preconditioning of recipients with irradiation or chemotherapy that often induces high toxicity. Here the authors show that antibody-drug-conjugate to CD117, a H...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Agnieszka Czechowicz, Rahul Palchaudhuri, Amelia Scheck, Yu Hu, Jonathan Hoggatt, Borja Saez, Wendy W. Pang, Michael K. Mansour, Tiffany A. Tate, Yan Yi Chan, Emily Walck, Gerlinde Wernig, Judith A. Shizuru, Florian Winau, David T. Scadden, Derrick J. Rossi
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/9ffac621975f4bccb6eaeafd10b5ba55
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Hematopoietic stem cell (HSC) transplantation is a desirable treatment for many non-malignant and malignant diseases, but its use requires preconditioning of recipients with irradiation or chemotherapy that often induces high toxicity. Here the authors show that antibody-drug-conjugate to CD117, a HSC marker, allows specific and efficient preconditioning for HSC therapy.

Ejemplares similares